Berlin, Germany-based Fosanis, which develops prescription digital therapeutics for all oncological indications, picked up investments from existing shareholder Ananada Impact Ventures, as well as new investors Debiopharm Innovation Fund, Ship2B Ventures and Equity Pitcher.
According to a news release, Fosanis’ Mika digital therapeutics platform represents the first of its kind in Germany. The company designed it to deliver evidence-based digital interventions with a view to supporting cancer patients as they cope with the challenges of the disease and treatment process.
Fosanis said the capital raised in the Series A will support the expansion of Mika into international terrain, as Fosanis plans to enter the United Kingdom healthcare ecosystem in 2022. The company also wants to partner with renowned international cancer research centers to conduct more studies on the impact of AI-driven personalization in digital interventions.
“Cancer knows no boundaries. Helping people affected by cancer shouldn’t either”, Mika founder and Managing Director Dr. Jan Simon Raue said in the release. “We have developed Mika to bring back some of the control when guidance and support is most needed: from diagnosis all the way through the therapy process. Our mission is to empower everyone affected by cancer.
“Knowing that every cancer patient is a human being with individual needs, Mika provides personalized and comprehensive cancer therapy support, combining the latest insights in cancer research with 24/7 hands-on help wrapped up in an easy-to-handle and engaging digital tool.”
